Moreover, in our validation cohort, IP6K2 was elevated in patients with advanced stages of glioma (III + IV vs I + II, P = 0.009) and metastatic glioma (P = 0.026) (Table 1). The gene discussed is IP6K2; the disease is central nervous system cancer.